Illumina ( (ILMN) ) has released its Q3 earnings. Here is a breakdown of the information Illumina presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Illumina, Inc. is a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets with innovative solutions in the life sciences sector.
In its third-quarter earnings report for fiscal year 2025, Illumina reported stable revenue figures, with a total of $1.08 billion, mirroring the same period last year. The company highlighted its strategic advancements and growth outside of China, alongside a focus on enhancing clinical market performance.
Key financial metrics for the quarter included a GAAP operating margin of 21.0% and a non-GAAP operating margin of 24.5%. The company achieved a GAAP diluted EPS of $0.98 and a non-GAAP diluted EPS of $1.34. Illumina also generated $284 million in cash from operations and repurchased 1.2 million shares for $120 million. Notably, the company launched several new products and expanded its personalized cancer care efforts through strategic partnerships.
Looking ahead, Illumina expects a slight decline in constant currency revenue for the fiscal year, with anticipated growth outside China. The company projects a non-GAAP operating margin between 22.75% and 23% and a non-GAAP diluted EPS ranging from $4.65 to $4.75, reflecting an upward revision from previous guidance.
Overall, Illumina’s management remains optimistic about its strategic initiatives and growth prospects, focusing on innovation and market expansion to drive long-term financial targets.